STOCK TITAN

Neuronetics, Inc. SEC Filings

STIM NASDAQ

Welcome to our dedicated page for Neuronetics SEC filings (Ticker: STIM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Neuronetics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.

Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Neuronetics's regulatory disclosures and financial reporting.

Rhea-AI Summary

CONLEY SHERYL L reported acquisition or exercise transactions in this Form 4 filing.

Neuronetics, Inc. director Sheryl L. Conley reported receiving an equity award in the form of restricted stock units. The award covers 30,000 RSUs, with no cash purchase price. Each RSU represents the right to receive one share of Neuronetics common stock.

The RSUs vest on the earlier of May 28, 2027, or her Board-approved separation from service or a change in control of Neuronetics, in each case conditioned on her continuous service through that date. After this grant, Conley holds 251,716 shares of common stock directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Neuronetics, Inc. director Robert Cascella received a grant of 36,250 restricted stock units of common stock as equity compensation. The award has no cash exercise price and will vest on the earlier of May 28, 2027, or a Board-approved separation or change in control, subject to his continuous service. After this grant, Cascella holds 625,017 shares of Neuronetics common stock directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Neuronetics, Inc. director Avinash Amin reported an equity compensation grant in the form of 30,000 restricted stock units of common stock. The award vests on the earlier of May 28, 2027, a Board-approved separation of service, or a change in control, in each case subject to his continuous service. Each RSU converts into one share of common stock upon vesting. Following this grant, he holds 72,500 shares directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Neuronetics, Inc. reported the voting results from its Annual Meeting of Stockholders. A total of 55,950,118 shares of common stock, representing approximately 80.41% of shares outstanding and eligible to vote, were present in person or by proxy, establishing a quorum.

All seven director nominees were elected to one-year terms with individual support levels ranging from about 28.5 million to 34.5 million votes. Stockholders also ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.

On a non-binding advisory basis, stockholders approved executive compensation with 29,133,360 votes for and 11,503,294 against. They also approved the Neuronetics, Inc. 2026 Equity Incentive Plan, which received 23,802,955 votes for and 16,651,661 against, with additional abstentions and broker non-votes on both proposals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Neuronetics, Inc. investor Jorey Chernett reports a 15.17% ownership stake in the company’s common stock. As of the close of business on May 26, 2026, he beneficially owned 10,553,988 shares, based on 69,587,840 shares outstanding as of May 1, 2026.

The filing states that these shares were purchased with personal funds for an aggregate price of approximately $20,619,936. Chernett holds sole voting and sole dispositive power over all reported shares, with no shared voting or dispositive authority. An exhibit lists individual share transactions since the prior amendment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
ownership
-
Rhea-AI Summary

Neuronetics, Inc. reported that it has updated the consulting arrangement with Francis X. Brown III, who serves as its Interim Principal Financial and Accounting Officer. Mr. Brown was previously engaged under an agreement dated April 22, 2026 and began serving as Interim PAO on May 5, 2026.

Under the new Amended and Restated Consulting Agreement dated May 18, 2026, his role is clarified to include ongoing service as Interim PAO until the company hires a full-time controller and a full-time principal financial and accounting officer or another written end date is agreed. His compensation is now set at $26,000 per month, replacing the earlier $25,000 fee for his interim services.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
Rhea-AI Summary

Neuronetics, Inc. former EVP, CFO and Treasurer Steven Pfanstiel corrected a prior insider report and now shows an open‑market sale of 8,569 shares of common stock on March 19, 2026 at a weighted average price of $1.34 per share.

The footnotes explain these were non‑discretionary sales made to satisfy his tax withholding obligation upon vesting of a performance restricted stock unit award. After this transaction, he directly holds 836,643 shares of Neuronetics common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Neuronetics, Inc. large shareholder Jorey Chernett bought 100,000 shares of common stock in an open-market transaction. The shares were purchased at an average price of $1.17 per share. Following this buy, Chernett directly holds 10,553,988 Neuronetics shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Neuronetics, Inc. disclosed an initial statement of beneficial ownership for interim principal accounting officer Francis X. Brown III. The Form 3 shows he directly holds 19,968 shares of Common Stock as of the reported date, with no buy or sell transactions indicated.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Neuronetics, Inc. large shareholder Jorey Chernett reported an open-market purchase of 475,000 shares of Common Stock. The shares were bought at a weighted average price of $1.34 per share in multiple trades. After this transaction, Chernett directly holds 10,453,988 shares of Neuronetics common stock.

The filing notes that individual trade prices on the transaction date ranged from $1.27 to $1.36 per share, and Chernett has agreed to provide full trade-level detail upon request.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

How many Neuronetics (STIM) SEC filings are available on StockTitan?

StockTitan tracks 102 SEC filings for Neuronetics (STIM), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Neuronetics (STIM)?

The most recent SEC filing for Neuronetics (STIM) was filed on May 29, 2026.